Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Downgrades Neurocrine Biosciences to Sector Perform, Lowers Price Target to $90

RBC Capital analyst Brian Abrahams downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Outperform to Sector Perform and lowers the price target from $122 to $90.
byBenzinga Newsdesk
January 18, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Brian Abrahams downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Outperform to Sector Perform and lowers the price target from $122 to $90.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0